Abstract AB1252 – Table 1. Characteristics of patients with RA and comorbidities

<table>
<thead>
<tr>
<th>Pain medication</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-steroidal</td>
<td>12</td>
<td>52</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>67</td>
<td>23</td>
</tr>
<tr>
<td>Anti-inflammatory drugs</td>
<td>54</td>
<td>21</td>
</tr>
<tr>
<td>All</td>
<td>70</td>
<td>21</td>
</tr>
</tbody>
</table>

Conclusions: Rheumatoid arthritis is a pain associated condition; two thirds of patients are using of pain medications mainly women; the most prescribed medication was paracetamol or opioids, coinciding with other studies. This descriptive study is useful for further studies to develop analgesics in Latin America.

REFERENCES:

Disclosure of Interest: None declared

AB1253

ANALGESIC DRUGS AND RISK OF ISCHAEMIC STROKE IN PATIENTS WITH OSTHEOARTRITIS: A REAL WORLD DATA CASE-CONTROL STUDY

A. Gomez-Lumbrañas, R. Vives, M. Giner-Soriano, H. Pera, M. Fradera, J. Marsal, R. Morros, A. Medicines Research Unit, Institut Universitari d’Investigació en Atenció Primària (IDiAP/Goi), Barcelona; Institut d’Investigació i Innovació Parc Taulí, Corporació Sanitària Parc Taulí, Sabadell; Universitat Autònoma de Barcelona; Institut Català de la Salut, Barcelona; 1Unidad de Soporte a la Recerca, Institut Universitari d’Investigació en Atenció Primària (IDiAP/Goi), Lleida, Spain

Background: Pharmacological treatment of osteoarthritis (OA) usually include analgesics, non-steroidal anti-inflammatory drugs (NSAID) and symptomatic slow-acting drugs in OA (SYSADOA). The association between these groups of drugs and the risk of ischaemic stroke has not been properly addressed.

Objectives: To analyse the risk of stroke in patients using analgesics, NSAID and SYSADOA drugs.

Methods: We used a population-based patient hospital registry to identify all patients with a first-ever stroke discharge diagnosis between 2009–2015. Cases were matched to controls obtained from the Information System for Research in Primary Care (SIDIA) database. Information on drug exposure was obtained from invoice data from pharmacies. Crude and adjusted odds ratios (OR, ORadj) and their 95% confidence interval (95% CI) were calculated using multivariate models of conditional logistic regression for the next pharmacological groups and individual agents of each group: acetic acid derivatives, oxicsams, propionic acid and derivatives, coxibs, SYSADOA and analgesics (opioids, metamizol and paracetamol).

A cardiovascular risk score was calculated for each subject based on comorbidities.

Results: 12,616 cases were matched to 1,256 controls. Gender and age were similar. Among cases, 43% were women. The mean age was 72.6 (IQR 68–79) years and more cases were classified as high cardiovascular risk patients (n=5,111, 19.9%) than controls (n=2,151, 10.0%). Mortality in the following year after the index date was higher for cases (n=2,633, 20.9%) than for controls (n=839, 6.5%). A higher percentage of cases had a previous diagnosis of ischaemic heart disease, 13.8% (n=1,745) vs 7.7% (n=9,656) of the controls. OA diagnosis was present in 2,823 (22.4%) cases and in 29,098 (23.2%) controls. Paracetamol was the most used drug (n=106,515, 77.3%) followed by ibuprofen (n=84,790, 61.5%).

Current users of acetic acid derivatives showed an increased risk of stroke [ORadj 1.10 (1.01–1.19)], so did diclofenac [ORadj 1.14 (1.04–1.25)]. Among the propionic acid derivatives, current users showed an increased risk [ORadj 1.24 (1.17–1.32)], dextropropoxyphene showed the highest risk [ORadj 1.42 (1.25–1.60)] and naproxen the lowest [ORadj 1.18 (1.02–1.37)]. The SYSADOA group did not show any increased risk for any type of exposure, with a decreased risk of 17% [ORadj 0.83 (0.77–0.91)] for lifetime glucosamine exposure and a 22% [ORadj 0.84 (0.78–0.90)] for chondroitin sulfate. Analgesics were the most consumed drugs, and cases were more exposed to all subgroups of analgesics than controls. While the non-adjusted OR showed an increased risk of stroke for lifetime exposure for all agents in this group, this association was not observed with the adjusted ORadj for fentanyl, neither buprenorphine, but it showed a risk for current users of metamizol [ORadj of 1.67 (1.56–1.80)], tramadol [ORadj 1.15 (1.06–1.24)] and paracetamol [ORadj 1.43 (1.37–1.51)].

Current exposure to NSAIDs, tramadol, metamizole and paracetamol is a risk factor for ischaemic stroke. Exposure to chondroitin sulphate and glucosamine are associated with a lower risk of ischaemic stroke.

Disclosure of Interest: None declared

AB1254

IMPROMING RHEUMATOLOGICAL CARE AND EDUCATION IN THE REPUBLIC OF MACEDONIA: A MODEL FOR PROMOTING RHEUMATOLOGICAL EDUCATION IN A DEVELOPING COUNTRY

V. Ognenovski1, M. Arsovska-Nalbanti2, M. Chichièk D, Calovski, J. Improving care and education in the Republic of Macedonia: model for rheumatologic care and arthritis (DAS-28) scores are as shown on table 1.

Abstract AB1254 – Table 1

<table>
<thead>
<tr>
<th>Rheumatoid Arthritis patients</th>
<th>Pre-intervention</th>
<th>Post-intervention</th>
<th>Statistical Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=115)</td>
<td>(n=86)</td>
<td></td>
</tr>
<tr>
<td>Patients taking methotrexate</td>
<td>44%</td>
<td>53%</td>
<td></td>
</tr>
<tr>
<td>Methotrexate dose</td>
<td>11.5 mg (10–15 mg)</td>
<td>13.9 mg (10–25 mg)</td>
<td>p&lt;0.0001</td>
</tr>
<tr>
<td>Combination therapy*</td>
<td>39%</td>
<td>38.8%</td>
<td>NS</td>
</tr>
<tr>
<td>Dual therapy</td>
<td>31%</td>
<td>35%</td>
<td>NS</td>
</tr>
<tr>
<td>Triple therapy*</td>
<td>3.5%</td>
<td>5%</td>
<td>NS</td>
</tr>
<tr>
<td>DAS-28 average</td>
<td>4.8</td>
<td>4.4</td>
<td>NS</td>
</tr>
</tbody>
</table>

MTX=methotrexate; *methotrexate, sulfasalazine, lefunomide, antimalarial (chloroquine, hydroxychloroquine)

Post intervention, more patients were taking methotrexate and at higher doses. Despite this trend, its average dose was less than 50% of its maximal dose (25 mg/week) commonly used in standard practice. The frequency of combination therapy remained unchanged. Likewise, no significant change in the DAS-28 score was observed.

Conclusions: Prior to launching the pilot, the rheumatologic care in this region was provided by visiting rheumatologists from the university clinic in the capital city. Initial assessment pointed to several obstacles: poor access and standard therapy that likely contributed to the prevalence of high disease activities. Our pilot succeeded in training a rheumatologist, thus reaching our primary goal of improving local access to rheumatologic care. The secondary goals of improving the quality of care as measured by standard therapy for rheumatoid arthritis and DAS-28 scores are as shown on table 1.
A REVIEW OF CASE-MIX AND CENTRE EFFECT ADJUSTMENT IN EARLY RHEUMATOID ARTHRITIS COHORTS

M. Yates, K. Bechman, S. Norton, J. Galloway, Academic Rheumatology, King's College London, London, UK

Background: Observational cohort studies have been utilised extensively in early Rheumatoid Arthritis (RA), regularly conducted across multiple centres spanning regional and national boundaries. Case-mix and centre effect are considerations essential for determining comparability of results, and likely prevalence of bias. There is currently no standardised approach for case-mix and centre effect adjustment in early RA observational cohorts.

Objectives: Describe the spectrum of methodologies used to address case-mix and centre level effects on outcomes in multi-centre early RA observational cohort studies.

Methods: Inclusion criteria were cohorts recruiting from 2 or more centres with 100 or more subjects, with a Rheumatologist diagnosis of RA or EIA within the last 24 months. A systematic electronic search of publications was undertaken. Papers were reviewed by two researchers independently. Reference lists of included papers were reviewed for further relevant publications. A search of all included papers' authors was also conducted. Detail on cohort characteristics, case-mix data collection and adjustment, and consideration of centre-level effect in analyses were collected.

Results: 1047 papers were identified from the initial search. A total of 20 unique cohorts were identified. Reference review and author search produced 14 more, to make a total of 34 unique observational cohorts drawn from 205 papers. The cohorts were mainly conducted in Europe (24/34, 71%), With 2 (6%) from less economically developed regions. The period of data collection was between 1955 and 2017.

Case-mix: All cohorts considered case-mix in some form (e.g. age and gender), but with heterogenous approaches. The figure displays the relative frequencies of sociodemographic variable consideration across all included papers.

Centre effect: 18/205 (9%) of the included papers accounted for centre in their results, utilising a range methodologies. Where reported, centre had a significant impact.

Conclusions: The degree of case-mix reporting varied widely, and few studies addressed centre effect. Where analysed, a centre level impact was clearly apparent. A failure to incorporate centre into analyses can lead to unreconised bias as a result of confounding by centre. It must be acknowledged that including case-mix variables and adjusting for centre substantially reduces power, and it is likely that many of the reported observations may have lost statistical significance had case-mix and centre effect been addressed more completely. This is the first systematic review of centre effect and case-mix in early RA, and highlights a challenging field deserving further research.

Disclosure of Interest: None declared

DEVELOPMENT OF A NATIONAL SERVICE FOR BIOLOGIC DRUG MONITORING

M.E. Perry, on behalf of Effective Prescribing Programme Biologics Working Group, National Services Scotland. Rheumatology, ROYAL ALEXANDRA HOSPITAL, Paisley, UK

Background: Monitoring serum levels of biological drugs has well recognised benefits for patients and health services. These include appropriate dosing, avoidance of overtreatment, identification of drug failure due to immunogenicity, cost and facilitation of switching therapy.1

Objectives: To establish a national service for monitoring serum levels of biological drugs.

Methods: National Services Scotland established a working group comprised of clinicians, lead pharmacist and Director of Public Health to help optimise biological drug prescribing. (Effective Prescribing Programme Biologics –EPPB). It was recognised that ad-hoc biologic drug monitoring (BM) posed a risk of variation in standards and inequity of access. Existing test volume and cost was established and a business case submitted to the CEO’s of each Health Board in Scotland for a national service, testing adalimumab and infliximab twice yearly in 2265 patients. Potential cost savings based on drug withdrawal of 2.5%, 5%, 10%, and 15% in gastroenterology patients ranged from 400,000Euro to 3.5 million Euro. Additional savings for dose reduction in rheumatology patients were not costed but likely to incur further financial advantage.

Results: The case was accepted and service tendered. A single site in Glasgow will run the assays (purchased from Grifols) commencing December 2017. The cost modelling predicts a 50% reduction in cost per test compared to existing arrangements. Cost for the whole service will be divided between the commissioning Health Boards with outlay proportional to patient population. The EPPB developed a specialist specific advice and an ordercomm with minimum dataset accessible from all Health Boards with the option of retrospective interrogation. A national educational event is scheduled to improve clinician confidence and awareness.

Conclusions: To our knowledge this is the first national fully funded biologic drug monitoring service with access to all users of biological drugs. Its introduction will: 1. Support the implementation of national standards of care to ensure the effective and cost effective use of biologic medicines 2. Ensure equity of access to BM across Health Boards. 3. Provide a stronger position for procurement of biologic drugs (uncomplicated by additional service offerings) 4. Provide a sustainable service for Scotland, independent of the drug manufacturer.

REFERENCE:

Disclosure of Interest: None declared

AB1255

A REVIEW OF CASE-MIX AND CENTRE EFFECT ADJUSTMENT IN EARLY RHEUMATOID ARTHRITIS COHORTS

AB1256

DEVELOPMENT OF A NATIONAL SERVICE FOR BIOLOGIC DRUG MONITORING

AB1257

IMPACT OF A SYSTEMATIC SCREENING OF MULTIMORBIDITIES IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES

M. BEURAI-WEBER1, A. JAUSSENTA, JAUSSENTE2, G.DU. CAILAR2, M.-C. PICOT2, F. ROUBLLE2, J.-D. COHEN1, J. MOREL1, J. BOUSQUET3, P. FESLER4, B. COMBE1, C. DAEN1, 1Rheumatology Department; 2Department of medical information; 3Internal medicine and hypertension, Lapeyronie Hospital and Montpellier University; 4Department of cardiology, Arnaud de Villeneuve Hospital and Montpellier University; 5MACVIA-France, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France

Objectives: EUPLAR proposes to screen multimorbidities in chronic inflammatory rheumatic diseases. The aim of the study was to assess i) multimorbidities in patients with chronic inflammatory diseases, ii) how patients follow recommendations given after a systematic standardised multimorbidity screening.

Methods: Exams were performed during a 1 day multimorbidity clinic. Diabetes, hypertension, CVD damage, chronic respiratory diseases, osteoporosis and preventive measures were assessed. Advice, complementary exams and prescriptions were provided to patient and general practitioner after this check-up if needed. Patients were called 3 months later to assess the applications of the given recommendations.